Debananda Das
Staff Scientist
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Dr. Das obtained his M.S. in chemistry from the Indian Institute of Technology, Kanpur, in 1991, and a M.Tech. in chemical analysis from the Indian Institute of Technology, Delhi, in 1994. Working with Prof. Scott Whittenburg, he earned his Ph.D. in chemistry from the University of New Orleans in 1999, where he carried out computational studies on the structure of small molecules. He carried out his postdoctoral work on QM/MM methods and applications in the group of Dr. Bernard Brooks at NIH. In 2002, he joined Tripos, Inc., as an application scientist. He joined the HIV and AIDS Malignancy Branch (HAMB) at NCI in 2005. At HAMB, he works in a multi-disciplinary environment focusing on the design, synthesis and development of the next-generation of therapeutic agents against HIV and HIV-associated malignancies.
Research Interest
structure-based discovery and design of small molecule inhibitors, virtual screening for small molecule lead identification, anti-HIV inhibitors, structure-function relationships, computational structural biology and computational chemistry
Publications
-
Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D. P2′ benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuran moiety. Antimicrobial agents and chemotherapy. 2013 Oct 1;57(10):4920-7.
-
Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro. Antimicrobial agents and chemotherapy. 2013 May 1;57(5):2036-46.
-
Gómez PM, Amano M, Yashchuk S, Mizuno A, Das D, Ghosh AK, Mitsuya H. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. Antimicrobial agents and chemotherapy. 2013 Dec 1;57(12):6110-21.
